- Home
- IBRX vs XRAY Comparison
IBRX vs XRAY Comparison
Compare IBRX & XRAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- XRAY
- Stock Information
- Founded
- IBRX 2014
- XRAY 1899
- Country
- IBRX United States
- XRAY United States
- Employees
- IBRX N/A
- XRAY N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- XRAY Medical/Dental Instruments
- Sector
- IBRX Health Care
- XRAY Health Care
- Exchange
- IBRX Nasdaq
- XRAY Nasdaq
- Market Cap
- IBRX 2.3B
- XRAY 2.6B
- IPO Year
- IBRX N/A
- XRAY 1987
- Fundamental
- Price
- IBRX $2.26
- XRAY $12.55
- Analyst Decision
- IBRX Strong Buy
- XRAY Hold
- Analyst Count
- IBRX 6
- XRAY 12
- Target Price
- IBRX $9.83
- XRAY $18.30
- AVG Volume (30 Days)
- IBRX 9.4M
- XRAY 3.2M
- Earning Date
- IBRX 11-10-2025
- XRAY 11-06-2025
- Dividend Yield
- IBRX N/A
- XRAY 5.10%
- EPS Growth
- IBRX N/A
- XRAY N/A
- EPS
- IBRX N/A
- XRAY N/A
- Revenue
- IBRX $56,600,000.00
- XRAY $3,671,000,000.00
- Revenue This Year
- IBRX $629.94
- XRAY N/A
- Revenue Next Year
- IBRX $109.91
- XRAY $1.50
- P/E Ratio
- IBRX N/A
- XRAY N/A
- Revenue Growth
- IBRX 4227.22
- XRAY N/A
- 52 Week Low
- IBRX $1.83
- XRAY $11.69
- 52 Week High
- IBRX $5.88
- XRAY $24.86
- Technical
- Relative Strength Index (RSI)
- IBRX 39.09
- XRAY 42.35
- Support Level
- IBRX $2.30
- XRAY $12.26
- Resistance Level
- IBRX $2.67
- XRAY $13.19
- Average True Range (ATR)
- IBRX 0.12
- XRAY 0.34
- MACD
- IBRX -0.02
- XRAY 0.02
- Stochastic Oscillator
- IBRX 1.19
- XRAY 30.56
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About XRAY DENTSPLY SIRONA Inc.
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).